CD14 is a gene located on chromosome 5q31.3 that encodes the CD14 protein, a critical co-receptor for Toll-like receptor 4 (TLR4) involved in innate immune responses to bacterial lipopolysaccharide (LPS) and other pathogen-associated molecular patterns (PAMPs)[@ziegler1988]. CD14 is expressed primarily on monocytes, macrophages, neutrophils, and microglial cells in the brain, where it plays a pivotal role in mediating neuroinflammatory processes that contribute to neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), and multiple sclerosis (MS)[@liu2017].
The CD14 protein exists in two primary forms: membrane-bound CD14 (mCD14) expressed on the surface of myeloid cells, and soluble CD14 (sCD14) shed from the cell surface or produced by alternative splicing. Both forms participate in pattern recognition and immune signaling, though membrane-bound CD14 is primarily responsible for cellular activation in response to LPS and other ligands[@haziot1996].
The CD14 protein is a leucine-rich repeat (LRR) pattern recognition receptor with distinct structural features:
Extracellular Domain: The N-terminal portion contains multiple leucine-rich repeats (LRRs) that mediate pattern recognition. These LRRs form a horseshoe-shaped structure ideal for binding various pathogen-associated molecular patterns. The protein is heavily glycosylated, with N-linked glycosylation sites important for proper folding and function.
Membrane Anchoring: CD14 is attached to the cell membrane via a glycosylphosphatidylinositol (GPI) anchor at its C-terminus. This allows for clustering in lipid rafts and facilitates interaction with TLR4/MD2 complexes. The GPI anchor enables rapid redistribution to phagocytic cups during particle engulfment.
Soluble Form: Soluble CD14 (sCD14) is generated through proteolytic cleavage by matrix metalloproteinases (MMPs) or through alternative splicing. sCD14 retains the ability to bind LPS and can transfer it to TLR4, but typically triggers less robust signaling due to the lack of membrane-associated clustering.
CD14 functions as a crucial pattern recognition receptor in the innate immune system. Its primary roles include:
LPS Recognition: CD14 acts as the primary receptor for bacterial lipopolysaccharide (LPS), the major component of Gram-negative bacterial cell walls. CD14 facilitates the transfer of LPS to the TLR4/MD2 receptor complex, initiating downstream signaling cascades that lead to NF-κB activation and pro-inflammatory cytokine production[@haziot1996]. The binding affinity for LPS is in the nanomolar range, making CD14 one of the highest-affinity LPS receptors known.
Pattern Recognition: Beyond LPS, CD14 recognizes a broad range of PAMPs including:
Cellular Activation: Upon ligand binding, CD14-mediated signaling triggers:
Soluble CD14 serves distinct functions:
Within the central nervous system, CD14 is expressed primarily on microglia, the resident immune cells of the brain. Microglial CD14 plays unique roles in brain homeostasis:
Surveillance: Resting microglia express CD14 at low levels and use it to survey the environment for danger signals. CD14 enables rapid detection of pathogens or endogenous damage signals.
Phagocytosis: CD14 facilitates the recognition and engulfment of cellular debris, amyloid deposits, and pathogens. This function is critical for maintaining brain homeostasis and clearing pathological protein aggregates.
Neuroinflammation: Upon activation, microglial CD14 expression increases substantially, leading to enhanced pro-inflammatory cytokine production. This can be protective when transient but becomes pathological when chronic.
CD14 plays a significant role in AD pathogenesis through multiple mechanisms:
Amyloid-Beta Mediated Inflammation: CD14 on microglia recognizes amyloid-beta (Aβ) aggregates as endogenous danger signals. This interaction triggers microglial activation, leading to the release of pro-inflammatory cytokines, reactive oxygen species, and nitric oxide that contribute to synaptic loss and neuronal death[@zhang2018]. Studies have demonstrated that CD14 deficiency in mouse models results in reduced Aβ-induced neuroinflammation and improved cognitive function.
The interaction between Aβ and CD14 is mediated through the N-terminal LRR domain, which can bind Aβ fibrils with moderate affinity. This binding is distinct from LPS recognition and involves different structural elements of the CD14 protein.
TLR4/CD14 Signaling: The TLR4/CD14 complex is a primary pathway through which Aβ activates innate immune responses in the brain[@kwon2019]. This signaling contributes to:
The downstream signaling involves MyD88-dependent activation of NF-κB, leading to transcription of pro-inflammatory genes. In AD brain, this pathway is chronically activated, creating a feed-forward loop where Aβ triggers inflammation, which then promotes more Aβ production and aggregation.
Genetic Associations: Several studies have identified CD14 polymorphisms associated with AD risk. The CD14 rs2569190 promoter polymorphism (-260C>T) has been linked to altered CD14 expression and modified AD risk in population studies[@zhang2019][@wood2023].
The T allele of rs2569190 is associated with increased CD14 expression and has been linked to:
Biomarker Potential: Soluble CD14 levels in cerebrospinal fluid (CSF) have been investigated as a potential biomarker for neurodegenerative diseases, with elevated levels correlating with disease severity and progression[@liu2022].
CSF sCD14 levels show:
In Parkinson's disease, CD14 contributes to neuroinflammation and dopaminergic neurodegeneration:
LPS-Induced Model: In models of LPS-induced dopaminergic degeneration, CD14 mediates microglial activation and subsequent loss of substantia nigra pars compacta neurons[@lee2020]. CD14-deficient mice show resistance to LPS-induced neurotoxicity, highlighting its critical role.
The LPS model is particularly relevant to PD because:
Alpha-Synuclein Fibrils: Recent research demonstrates that CD14 interacts with alpha-synuclein fibrils, facilitating microglial activation and inflammatory responses that may accelerate disease progression[@fan2021].
This interaction involves recognition of the fibrillar form of alpha-synuclein by CD14's pattern recognition domains. Binding triggers:
MPTP Toxicity: Studies in MPTP-induced parkinsonian models show that CD14 knockout mice exhibit enhanced protection against dopaminergic neuron loss, supporting the involvement of CD14-mediated inflammation in PD pathogenesis[@cheng2021].
The MPTP model reveals that:
Lrrk2 Interaction: Recent studies suggest interactions between CD14 signaling and LRRK2, a major PD risk gene. LRRK2 mutations may affect microglial inflammatory responses mediated through CD14.
CD14 is involved in the neuroinflammatory processes characteristic of multiple sclerosis:
Blood-Brain Barrier Breakdown: CD14-mediated signaling contributes to endothelial cell activation and blood-brain barrier (BBB) disruption in MS[@park2022].
The mechanisms include:
Lesion Microglia: CD14+ microglia are abundant in MS lesions, where they contribute to demyelination and axonal damage through pro-inflammatory cytokine production.
Lesion characterization shows:
Therapeutic Target: Modulating CD14 signaling represents a potential therapeutic strategy for reducing harmful neuroinflammation in MS.
Amyotrophic Lateral Sclerosis (ALS): CD14-mediated microglial activation contributes to motor neuron injury in ALS models. Studies show:
Vascular Cognitive Impairment: CD14 contributes to neuroinflammation in vascular dementia through TLR4-dependent mechanisms[@johnson2020].
Frontotemporal Dementia: Elevated CD14 expression has been observed in FTD brain tissue.
Huntington's Disease: CD14 polymorphisms may modify disease onset and progression.
CD14 engages multiple downstream signaling pathways:
The MyD88-dependent pathway is the primary signaling route for CD14/TLR4 activation:
Adaptor Recruitment: Upon ligand binding, TLR4 recruits the adaptor protein MyD88 through TIR domain interactions.
Kinase Activation: MyD88 recruits IRAK4 and IRAK1, leading to TRAF6 activation.
NF-κB Activation: TRAF6 activates the IKK complex, leading to IκB degradation and NF-κB nuclear translocation.
Gene Transcription: NF-κB drives transcription of pro-inflammatory genes including cytokines, chemokines, and adhesion molecules.
MAPK Activation: Parallel signaling through TAK1 activates p38, JNK, and ERK MAP kinases.
The TRIF-dependent pathway provides delayed and distinct responses:
TRIF Recruitment: TLR4 signaling also recruits TRIF through MyD88-independent mechanisms.
IRF Activation: TRIF activates IRF3 and IRF7, leading to type I interferon production.
Late Phase NF-κB: TRIF also contributes to delayed NF-κB activation.
CD14/TLR4 signaling can also occur through endocytosis:
Receptor Internalization: TLR4/CD14 complexes are internalized via clathrin-mediated endocytosis.
Signaling from Endosomes: Endosomal TLR4 continues to signal through TRIF.
Autophagy Connection: CD14 is involved in the autophagy pathway through interactions with LC3.
Given its central role in neuroinflammation, CD14 represents a promising therapeutic target:
Blocking Antibodies: Anti-CD14 monoclonal antibodies have shown promise in preclinical models by reducing Aβ-induced microglial activation and improving cognitive function[@kim2021].
Antibody-based approaches offer:
Small Molecule Inhibitors: CD14/TLR4 signaling inhibitors are under development for neurodegenerative diseases.
Current approaches include:
RNAi Approaches: CD14 siRNA delivery via nanoparticles represents a novel therapeutic strategy currently being explored[@chen2023].
Decoy Receptors: Soluble CD14 variants that act as decoys could potentially dampen excessive inflammation.
Recent research indicates that CD14 effects may be sex-specific, with males and females showing differential responses to CD14 modulation in AD pathogenesis[@yang2021]. This has implications for personalized therapeutic approaches.
Key differences include:
Key experimental approaches for studying CD14 in neurodegeneration:
CD14 serves as a critical interface between pattern recognition and neuroinflammatory responses in the brain. Its involvement in multiple neurodegenerative diseases makes it an attractive therapeutic target. However, the dual nature of CD14-mediated inflammation—protective in acute responses but pathological in chronic activation—presents a therapeutic challenge. Further research is needed to develop strategies that selectively modulate CD14 signaling without compromising essential immune functions.